Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test.

Tsui, Dana W Y; Blumenthal, Gideon M; Philip, Reena; Barrett, J Carl; Montagut, Clara; Bramlett, Kelli; Ladanyi, Marc; Ghosh, Soma

Tsui, Dana W Y; Blumenthal, Gideon M; Philip, Reena; Barrett, J Carl; Montagut, Clara; Bramlett, Kelli; Ladanyi, Marc; Ghosh, Soma.

Afiliação

Tsui DWY; Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center.
Blumenthal GM; Oncology Center of Excellence, Food and Drug Administration.
Philip R; Division of Molecular Genetics and Pathology, CDRH, Food and Drug Administration.
Barrett JC; Vice President, Oncology Translational Medicine, AstraZeneca.
Montagut C; Head of Gastrointestinal Cancer from Hospital Del Mar-IMIM, CIBERONC, Barcelona, Spain.
Bramlett K; Director, R&D, Life Sciences Group, Thermo Fisher Scientific.
Ladanyi M; Chief, Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center.
Ghosh S; Chief, Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center.

Clin Chem ; 66(3): 408-414, 2020 03 01.

Article em En | MEDLINE | ID: mdl-32091082

Assuntos

Biópsia Líquida/métodos; Biomarcadores Tumorais/genética; DNA Tumoral Circulante/análise; Receptores ErbB/genética; Regulamentação Governamental; Humanos; Neoplasias/patologia; Células Neoplásicas Circulantes/metabolismo; Células Neoplásicas Circulantes/patologia; Proteínas Proto-Oncogênicas p21(ras)/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biópsia Líquida Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biópsia Líquida Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article